Skip to content

ABOUT US

Who Are We?

About Kinoxis Therapeutics

Kinoxis Therapeutics Pty Ltd (Kinoxis) is a private, Australian-based, late preclinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney.  Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors. Kinoxis has also secured significant funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.

Our Team

The Kinoxis Executive Team

Hugh Alsop – Chief Executive Officer, Co-Founder

Hugh Alsop – Chief Executive Officer, Co-Founder

Hugh is an accomplished biotech executive with over 22 years of experience in drug development for global markets, pharmaceutical commercialization, international business development and partnering, general management and profit accountability.

Hugh has worked in executive positions for a wide spectrum of pharmaceutical and biotechnology companies, including Hatchtech, Acrux, Sigma Pharmaceuticals, Mayne Pharma, and Faulding Pharmaceuticals, and also serves as a non-executive Director on the Board of Australian biopharmaceutical companies, Dimerix Pty Ltd and Servatus Pty Ltd.

Associate Professor Michael Bowen – Chief Scientific Officer, Co-Founder

Associate Professor Michael Bowen is one of the lead inventors of the intellectual property licensed by the company. Michael’s behavioural neuroscience and neuropsychopharmacology research has played an important role in establishing the brain oxytocin system as a target of significant interest for treating substance abuse and social disorders. Michael led the Kinoxis-funded work assessing KNX100 in rodent models of agitation and aggression and substance use disorders.

Associate Professor Michael Bowen – Chief Scientific Officer, Co-Founder
Sharon Hanegraaf – Vice President, Drug Development

Sharon Hanegraaf – Vice President, Drug Development

Sharon has over 25 years of experience in international drug development spanning preclinical, clinical, drug development and product registration. Sharon specializes in regulatory strategy and CMC and has previously held regulatory affairs positions at pharmaceutical and biotechnology companies such as Prota Therapeutics, Hatchtech and Acrux.

Sharon has broad experience in various therapeutic indications, focusing on product commercialization in the US and other territories and has been involved in the successful approval of two drug products by the FDA, Axiron® and XeglyzeTM, originally developed in Australia.

Dr Tina Soulis – Vice President, Clinical Strategy & Development

Tina Soulis is a global leading expert in the design, management and implementation of clinical trials and has held various senior roles within the pharmaceutical and biotechnology industry for over 25 years. Tina has previously held an executive position at Neuroscience Trials Australia, a world-leading Contract Research Organisation specialising in all aspects of (neuroscience) clinical development, and she is a proactive member on various Australian and international clinical trial advocacy, policy, and neurology focused leadership groups.

Dr Tina Soulis – Vice President, Clinical Strategy & Development
Cameron Jones – Chief Financial Officer & Company Secretary

Cameron Jones – Chief Financial Officer & Company Secretary

Cameron is the managing director of Bio101, a financial services firm providing accounting, taxation and company secretarial services for companies in the life sciences sector. Cameron is a qualified Chartered Accountant and acts as a Company Secretary and CFO for Kinoxis, bringing his extensive accounting, business advisory and financial planning expertise.

Key People

Kinoxis advisory board and key people

Professor Michael Kassiou
Scientific Advisor

Professor Iain McGregor
 Scientific Advisor

Dr Marian Glynn
Toxicology Consultant (US)

Dr Ron Lawrence
CMC Consultant (UK)

Dr Nick Moore
Pharmacology Consultant

Dr Archie Thurston
ADME/PK Consultant

Board of Directors

Our Board of Directors

Dr Peter Devine
Chair

Dr Kathryn Sunn
Non-Executive Director

Dr Kathy Nielsen
Non-Executive Director

Dr John Kurek
Non-Executive Director

Follow us on social media

stay up to date with the latest in Kinoxis research & news